首页> 中文期刊>临床心身疾病杂志 >多烯紫杉醇联合奈达铂同步放疗治疗中晚期食管癌疗效及安全性研究

多烯紫杉醇联合奈达铂同步放疗治疗中晚期食管癌疗效及安全性研究

     

摘要

目的 探讨多烯紫杉醇联合奈达铂同步放疗治疗中晚期食管癌患者的疗效及安全性.方法 将68例中晚期食管癌患者采用随机数字表法分为两组,各34例.两组均给予三维适形放疗,研究组给予多烯紫杉醇联合奈达铂化疗,对照组给予紫杉醇联合顺铂化疗.比较两组临床疗效、不良反应发生率、治疗后不同时点生存率.结果 研究组总有效率及各时点生存率均显著高于对照组(P<0.05),各项不良反应发生率显著低于对照组(P<0.05).结论 多烯紫杉醇联合奈达铂同步放疗治疗中晚期食管癌效果显著,不良反应发生率低,有利于提高患者生存率,值得推广应用.%Objective To investigate the clinical effect and safety of docetaxel combined with nedaplatin concurrent radiotherapy in the treatment of tniddle-advanced stage esophagus cancer. Method 68 patients with middle-advanced stage esophagus cancer were randomly divided into two groups, each with 34 cases. The two groups were treated with three-dimensional conformal radiotherapy. On this basis, the study group was treated with docetaxel + nedaplatin chemotherapy, the control group was treated with paclitaxel + cisplatin chemotherapy. The clinical efficacy; ineidence of side effects and the survival rates at different time points between the two groups were compared. Results The total effective rate and the survival rates at different time points in the study group were significantly higher than those in the control group(P< 0.05), the incidence of side effects in the study group was lower than that in the control group (P<0.05). Conclusion Docetaxel combined with nedaplatin concurrent radiotherapy in the treatment of middle-advanced stage esophagus cancer have significant effect, the incidence of side effects is lower, it can improve the survival rate of patients, and it is worthy of popularization and application.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号